Mizuho analyst Vamil Divan reiterated a Neutral rating and $3.65 price target on Revance Therapeutic (NASDAQ: RVNC)The analyst comments "A ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE